Amgen WorldwideCLINICAL TRIALS
Vectibix®
Generic Name: Panitumumab
| Study ID | Studied Indication or Disease | Phase | Study Title | Synopsis |
|---|---|---|---|---|
| 20020408 | Treatment of subjects with metastatic colorectal cancer who had disease progression during or after prior standard fluoropyrimidine, irinotecan, and oxaliplatin chemotherapy | 3 | An Open-label, Randomized, Phase 3 Clinical Trial of ABX-EGF Plus Best Supportive Care Versus Best Supportive Care in Subjects with Metastatic Colorectal Cancer |  |
| 20025409 | Metastatic Colorectal Cancer | 2 | A Clinical Trial of the Safety and Efficacy of ABX-EGF in Combination with Irinotecan, Leucovorin, and 5-Fluorouracil in Patients with Metastatic Colorectal Cancer | |
| 20030167 | Treatment of subjects with metastatic colorectal cancer who had disease progression during or after prior standard fluoropyrimidine, irinotecan, and oxaplatin chemotherapy | 2 | A Phase 2, Multicenter, Single-arm Clinical Trial of ABX-EGF Monotherapy in Subjects With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy | |
| 20030194 | Third- or fourth-line monotherapy in subjects with metastatic colorectal cancer | NA | A Multicenter Open-Label Single Arm Clinical Trial to Determine the Safety of ABX-EGF Extended Therapy in Subjects with Metastatic Colorectal Cancer | |
| 20030250 | Third- or fourth-line monotherapy in subjects with metastatic colorectal cancer whose tumors express low or negative EGFr levels by immunohistochemistry | 2 |
A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Whose Tumors Express Low or Negative EGFr Levels by Immunohistochemistry Following Treatment with Fluoropyrimidine, Irinotecan,and Oxaliplatin Chemotherapy
| |
| 20030251 | Advanced Solid Tumors | 1 | An Open-label Clinical Trial Evaluating the Safety and Pharmacokinetics of 2 Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors | |
| 20040192 | Advanced Solid Tumors | 1 | A Phase 1 Clinical Study of ABX-EGF (Panitumumab) Evaluation of the Safety and Pharmacokinetics of ABX-EGF in Japanese Subjects with Advanced Solid Tumors | |
| 20040235 | Subjects with loco-regionally advanced squamous cell carcinoma of the head and neck who are candidates for IC followed by CRT | 1b | An Open-label, Multi-Center, Dose-finding Study to Evaluate the Safety and Tolerability of AMG 706 or Panitumumab when Administered with Induction Chemotherapy (IC) and/or Chemo-radiotherapy (CRT) in the Treatment of Subjects with Loco-regionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) | |
| 20040249 | First-line treatment of metastatic colorectal cancer | 3B | A Randomized, Open-label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab with and without Panitumumab in the First-line Treatment of Subjects with Metastatic Colorectal Cancer | |
| 20050181 | 2nd line metastatic colorectal cancer in combination with chemotherapy | 3 | A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Chemotherapy to the Efficacy of Chemotherapy Alone in Patients with Previously Treated Metastatic Colorectal Cancer | |
| 20050203 | 1st line metastatic colorectal cancer in combination with chemotherapy | 3 | A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Oxaliplatin/ 5-fluorouracil/ leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ leucovorin Alone in Patients with Previously Untreated Metastatic Colorectal Cancer | |
| 20050216 | Subjects with Metastatic Colorectal Cancer Who Developed Progressive Disease or Relapsed While on or After Prior Fluoropyrimidine, Irinotecan and Oxaliplatin Chemotherapy | 2 | A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF (Panitumumab) Monotherapy in Japanese Subjects with Metastatic Colorectal Cancer Who Developed Progressive Disease or Relapsed While on or After Prior Fluoropyrimidine, Irinotecan and Oxaliplatin Chemotherapy. | |
| 20050236 | Cancer of Head and Neck | 2 | A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy with or without Panitumumab as First-line Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer, and Cross-over Second-line Panitumumab Monotherapy of Subjects who Fail the Combination Chemotherapy Only Arm | |
| 20050251 | Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck | 3 | A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck | |
| 20050252 | Solid Tumors | 1 | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children with Solid Tumors | |
| 20060141 | Second-line metastatic colorectal cancer (mCRC) wild-type KRAS tumors in combination with chemotherapy. | 2 | A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI with Either Panitumumab or Bevacizumab as Second-line Treatment in Subjects with Metastatic Colorectal Cancer with Wild-type KRAS tumors | |
| 20060277 | Second-line metastatic colorectal cancer (mCRC) | 2 | Multi-center, Open-label, Single-arm Trial Evaluating Panitumumab in Combination with FOLFIRI Therapy Following First-line FOLFOX and Bevacizumab Treatment of Metastatic Colorectal Cancer | |
| 20060314 | Metastatic colorectal cancer (mCRC) | 2 | A Single-arm Multicenter Phase 2 Study of Panitumumab in Combination with Irinotecan/5-fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer | |
| 20060332 | Subjects with metastatic colorectal cancer (mCRC) with disease progression on or following fluoropyrimidine-, oxaliplatin-, and/or irinotecan-containing chemotherapy regimens | 1b/2 | A Phase 1b/2 Trial of AMG 655 in Combination with Panitumumab in Subjects with Metastatic Colorectal Cancer | |
| 20060447 | wild-type KRAS metastatic colorectal cancer | 1b/2 | A Randomized, Phase 1b/2 Trial of AMG 102 or AMG 479 in Combination with Panitumumab versus Panitumumab Alone in Subjects with Wild-Type KRAS Metastatic Colorectal Cancer | |
| 20060542 | Unresectable or metastatic adenocarcinoma of the Pancreas | 2 | Phase II, Multi-center, Open-label, Single-Arm Study using Gemcitabine and Panitumumab in the First-line Treatment of Subjects with Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas | |
| 20062010 | Unresectable metastatic colorectal cancer (mCRC) expressing wild-type (wt) KRAS | 1 | A Phase I, Open-label Study to Determine the Effect of Panitumumab on the Pharmacokinetics of Irinotecan in Subjects with Unresectable Metastatic Colorectal Cancer | |
| 20062079 | Unresected, locally advanced squamous cell carcinoma of the head and neck | 2 | A Phase 2 Randomized Trial of Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck | |
| 20062080 | Unresected, locally advanced squamous cell carcinoma of the head and neck | 2 | A Phase 2, Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck | |
| 20062088 | Squamous Cell Carcinoma of Head and Neck (SCCHN) | 2 | Phase 2, Single-Arm, Open-Label, Multi-Center Trial of Second-Line Panitumumab Monotherapy in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck | |
| 20070509 | Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer | 2 | A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer | |
| 20070820 | Metastatic colorectal cancer expressing wild type (wt) KRAS and refractory to irinotecan- and oxaliplatin-containing regimens, or refractory to oxaliplatin-containing regimens | 2 | Phase 2 Study of Panitumumab Plus Irinotecan Followed by Panitumumab Plus AMG 479 in Subjects With Metastatic Colorectal Carcinoma Expressing Wild-type KRAS and Refractory to Oxaliplatin- or Irinotecan- and Oxaliplatin containing Regimens to Evaluate Mechanisms of Acquired Resistance to Panitumumab | |
| 20080008 | Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck | 2 | A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck | |
| 20080763 | Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer | 3 | A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer | |
| 20100007 | Chemorefractory, Wild-type KRAS, Metastatic Colorectal Cancer (mCRC). | 3 | Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects With Chemorefractory Wild-type KRAS Metastatic Colorectal Cancer | |
| 20101120 | Patients with mCRC treated with Vectibix | Observational Study | Medical Records Review to Describe the Patterns of KRAS/RAS Testing and Vectibix Use in Europe. | |